PTEN and breast cancer: In a randomized non comparative phase II trial of Anastrozole or Fulvestrant as neoadjuvant endocrine therapy for post-menopausal HR+ BC patients, responders were found to harbor a significant overexpression of PTEN-related encoding gene (TPTE), as compared to non-responders, and this upregulation was maintained even after months of neoadjuvant endocrine therapy.